[Federal Register Volume 88, Number 132 (Wednesday, July 12, 2023)]
[Notices]
[Pages 44318-44331]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-14704]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Reorganization of the National Center for Emerging and Zoonotic 
Infectious Diseases

AGENCY: Centers for Disease Control and Prevention (CDC), the 
Department of Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY:  CDC has modified its structure. This notice announces the 
reorganization of the National Center for Emerging and Zoonotic 
Infectious Diseases (NCEZID). NCEZID reorganized to improve 
collaboration between science and public health programs within NCEZID 
as well as with our partners across and outside the agency, which will 
increase our public health impact.

DATES: This reorganization was approved by the Director of CDC on June 
28, 2023.

FOR FURTHER INFORMATION CONTACT: Kimberly Thurmond, Office of the Chief 
Operating Officer, Office of the Director, Centers for Disease Control 
and Prevention, 1600 Clifton Road NE, MS TW-2, Atlanta, GA 30329. 
Telephone 770-488-4401; Email: [email protected].

SUPPLEMENTARY INFORMATION: Part C (Centers for Disease Control and 
Prevention) of the Statement of Organization, Functions, and 
Delegations of Authority of the Department of Health and Human Services 
(45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296, 
October 20, 1980, as amended most recently at 88 FR 9290-9291, dated 
February 13, 2023) is amended to reflect the reorganization of the 
National Center for Emerging and Zoonotic Infectious Diseases, Centers 
for Disease Control and Prevention. Specifically, the changes are as 
follows:
    I. Under Part C, Section C-B, Organization and Functions, insert 
the following:

 National Center for Emerging and Zoonotic Infectious Diseases 
(CR)
 Office of the Director (CR1)
 Division of Foodborne, Waterborne, and Environmental Diseases 
(CRB)
 Office of the Director (CRB1)
 Enteric Diseases Epidemiology Branch (CRBB)
 Enteric Diseases Laboratory Branch (CRBC)
 Outbreak Response and Prevention Branch (CRBD)
 Waterborne Disease Prevention Branch (CRBE)
 Mycotic Diseases Branch (CRBG)
 Division of Global Migration Health (CRC)
 Office of the Director (CRC1)
 Travel Risk Assessment and Mitigation Branch (CRCB)
 Immigrant and Refugee Health Branch (CRCC)
 Travelers' Health Branch (CRCD)
 Port Health Protection Branch (CRCE)
 Southern Border Health and Migration Branch (CRCG)
 Division of Healthcare Quality Promotion (CRD)
 Office of the Director (CRD1)
 Antimicrobial Resistance Coordination and Strategy Unit 
(CRD12)
 Immunization Safety Office (CRDB)
 Clinical and Environmental Microbiology Branch (CRDC)
 Prevention and Response Branch (CRDD)
 Surveillance Branch (CRDE)
 Epidemiology Research and Innovations Branch (CRDG)
 Healthcare Systems Strengthening, Resilience, and Training 
Branch (CRDH)
 International Infection Control Branch (CRDJ)
 Medical Product Safety Branch (CRDK)
 Division of High-Consequence Pathogens and Pathology (CRE)
 Office of the Director (CRE1)
 Prion and Public Health Office (CRE12)
 Viral Special Pathogens Branch (CREB)
 Poxvirus and Rabies Branch (CREC)
 Infectious Diseases Pathology Branch (CRED)
 Chronic Viral Diseases Branch (CREE)
 Bacterial Special Pathogens Branch (CREG)
 Division of Infectious Disease Readiness and Innovation (CRG)
 Office of the Director (CRG1)
 Arctic Investigations Program (CRGB)
 Epidemiology Laboratory Capacity and Informatics Branch (CRGC)
 Rapid Response Research and Surveillance Branch (CRGD)
 Office of Advanced Molecular Detection (CRGE)
 Division of Core Laboratory Services and Response (CRH)
 Office of the Director (CRH1)
 Advanced Diagnostics and Biotechnologies Branch (CRHB)
 Comparative Medicine Branch (CRHB)
 Preparedness, Response, and Outbreak Services Branch (CRHD)
 Laboratory Products and Services Branch (CRHE)
 Division of Vector-Borne Diseases (CRJ)
 Office of the Director (CRJ1)
 Arboviral Diseases Branch (CRJB)
 Bacterial Diseases Branch (CRJC)
 Dengue Branch (CRJD)
 Rickettsial Zoonoses Branch (CRJE)
 Division of Parasitic Diseases and Malaria (CRK)
 Office of the Director (CRK1)
 Malaria Branch (CRKB)
 Parasitic Diseases Branch (CRKC)
 Entomology Branch (CRKD)
 Laboratory Science and Diagnostics Branch (CRKE)

    II. Under Part C, Section C-B, Organization and Functions, retitle 
the following organizational units:

 Division of Global Migration and Quarantine to Division of 
Global Migration Health (CRC)
 Division of Scientific Resources to Division of Core 
Laboratory Services and Response (CRH)

    III. Under Part C, Section C-B, Organization and Functions, delete 
the mission or functional statements for and replace with the 
following:
    National Center for Emerging and Zoonotic Infectious Diseases (CR). 
The National Center for Emerging and Zoonotic Infectious Diseases 
(NCEZID) saves lives through the prevention, early detection, and 
control of infectious disease threats. In carrying out these 
activities, NCEZID: (1) works collaboratively across CDC and with 
external partners to conduct, coordinate, support, and evaluate public 
health efforts to prevent and minimize morbidity and mortality due to

[[Page 44319]]

infectious diseases, promoting a One Health approach involving the 
interface of animal, human, and environmental factors; (2) leads 
agency-wide efforts in planning for and responding to infectious 
disease outbreaks in the United States and around the world; (3) 
develops, evaluates, and advances science, programs, management, and 
operations toward meeting the agency's infectious disease-related 
mission and goals and improving the agency's response readiness; (4) 
conducts epidemiologic and laboratory science and applied research 
aimed at identifying risk factors and disease burdens and developing 
and implementing public health programs, practices, and policies for 
infectious disease prevention and control including increasing health 
equity; (5) works with domestic and global partners to provide 
technical and subject matter expertise in responding to outbreaks and 
in establishing, maintaining, and evaluating disease control and 
prevention programs; (6) supports a broad range of cross-cutting and 
collaborative programs aimed at enhancing response readiness and public 
health capacity at the local, state, and national levels; (7) works to 
improve the quality and safety of healthcare through efforts to reduce 
healthcare associated infections and antimicrobial resistance and to 
ensure the safety of medical products, including vaccines; (8) conducts 
activities to improve the safety of food and water and reduce related 
enteric illnesses; conducts activities to address diagnosis, 
prevention, and control of vector-borne diseases, including malaria, in 
the United States and globally; (9) administers a national public 
health program to prevent U.S. importation and spread of infectious 
diseases; (10) works with CDC colleagues and external partners to 
improve public health preparedness at the local, state, and national 
levels; and (11) works to increase public health prevention efforts for 
populations at increased risk for infectious diseases.
    Office of the Director (CR1). (1) provides leadership in 
developing, prioritizing, advancing, and evaluating the Center's 
science, programs, management, and operations toward meeting agency 
mission and goals; (2) advises the CDC Director and Immediate Office of 
the Director (IOD) on priority issues affecting the Center; (3) 
identifies and facilitates synergies within NCEZID, across CDC, and 
with external partners for enhancing infectious disease response 
readiness and addressing emerging and zoonotic infectious diseases 
domestically and globally; (4) enhances collaborations and partnerships 
across multiple disciplines, including human and animal health; and 
works to systematically reduce disparities related to emerging and 
zoonotic infectious diseases; (5) serves as the focal point and 
programmatic home for activities on One Health, an integrated approach 
to optimizing human and animal health that considers the 
interrelatedness among humans, animals, and their environments; (6) 
builds and manages a portfolio of One Health activities, plans, and 
accomplishments; (7) leads Center-wide enhancement of data systems to 
support predictive data science and rapid sharing of information, 
supported by modern information technology platforms and enterprise 
services that facilitate CDC's public health mission; (8) provides 
assay validation and surge testing support for outbreak response; (9) 
provides foundation for design control for assay development and 
supports compliance with agency quality plan; (10) maintains close 
programmatic oversight of the Division of Healthcare Quality 
Promotion's Antimicrobial Resistance Coordination and Strategy Unit and 
the Division of Infectious Disease Readiness and Innovation's Office of 
Advance Molecular Detection, assuring a direct line for communication 
with the directors of those programs; (11) provides leadership, 
guidance, and technical assistance on policy and communication issues 
affecting the center; (12) serves as liaison with CDC counterparts, 
CDC/IOD, other government agencies, and external partners on policy, 
program, legislative, communication, and budgetary issues related to 
NCEZID; (13) serves as the Designated Federal Official (DFO), provides 
leadership for, and manages the infectious diseases Board of Scientific 
Counselors, a chartered Federal advisory committee that advises on 
strategies, goals and priorities for CDC's infectious disease programs 
and research; (14) recruits and supports a strong, diverse Center-wide 
workforce and builds leadership at the division and branch levels to 
promote the integration of diversity into all aspects of the workforce; 
(15) ensures program accountability, supporting achievement of 
programmatic goals with measurable impact; (16) supports effective 
administrative services for NCEZID as well as effective cross-cutting 
scientific and program services for all CDC's infectious disease 
national Centers; and (17) provides staffing and support for emergency 
responses at program, division, Center, and agency levels.
    Division of Foodborne, Waterborne, and Environmental Diseases 
(CRB). The mission of the Division of Foodborne, Waterborne, and 
Environmental Diseases (DFWED) is to improve public health nationally 
and internationally through the prevention and control of disease, 
disability, and death caused by foodborne, waterborne, other enteric, 
and fungal infections. In carrying out its mission, DFWED: (1) develops 
and leads national surveillance platforms and conducts surveillance, 
investigations, and studies of foodborne bacterial diseases, waterborne 
diseases, and mycotic diseases to determine the sources and develop 
effective methods for diagnosis, prevention, and control; (2) conducts 
or participates in clinical, field, and laboratory research to develop, 
evaluate, and improve laboratory methodologies, materials, diagnostics, 
and therapeutic practices used for environmental detection, diagnosis, 
treatment, investigation, and control of foodborne and zoonotic 
bacterial diseases, water, sanitation, and hygiene-related diseases, 
and mycotic diseases, including those affected by changes in the 
environment or climate; (3) conducts environmental microbiology 
research activities at CDC through partnerships and external activities 
to promote research on prevention and control of infectious disease 
transmission from the environment to humans; (4) provides epidemiologic 
consultation, upon request, to state and local health departments, 
other Federal agencies, national and international health 
organizations, and ministries of health; (5) provides reference/
diagnostic services for foodborne and zoonotic bacterial diseases, 
waterborne bacterial and parasitic diseases, and mycotic diseases to 
state and local health departments, other Federal agencies, and 
national and international health organizations; (6) investigates 
outbreaks, conducts surveillance, and engages in research studies 
concerning the emergence and spread of antimicrobial resistant enteric 
and mycotic pathogens across the One Health spectrum; (7) provides 
scientific and technical assistance to other CDC components when the 
work requires unique expertise or specialized equipment not available 
in other components; (8) provides intramural and extramural technical 
expertise and assistance in professional training and proficiency 
testing activities; (9) serves as appropriately designated national and 
international reference centers for

[[Page 44320]]

various foodborne bacterial diseases, waterborne bacterial and 
parasitic diseases, and mycotic diseases; (10) develops clear health 
promotion strategies, campaigns, and messages to promote prevention and 
control, including strategies specifically aimed to improve the health 
outcomes of populations at disproportionate risk of these diseases; 
(11) coordinates with other Federal agencies and partners organizations 
to prevent foodborne, waterborne, other enteric, and mycotic diseases; 
(12) provides staffing and support for emergency responses at program, 
division, Center, and agency levels; and (13) trains Epidemic 
Intelligence Service (EIS) officers, fellows, students, staff, and 
visiting scientists from the United States and abroad.
    Office of the Director (CRB1). (1) directs and manages the programs 
and activities of DFWED; (2) provides leadership and guidance on 
policy, communication, prevention science, program planning and 
development, program management, and operations; (3) coordinates or 
assures coordination with the appropriate CDC and NCEZID offices on 
administrative and program matters; (4) reviews, prepares, and 
coordinates Congressional testimony and briefing documents related to 
enteric and fungal diseases and analyzes programmatic and policy 
implications of legislative proposals and analyzes programmatic and 
policy implications of legislative proposals; (5) represents CDC and 
NCEZID programs and prevention policies in meetings with governmental, 
private, and international organizations; (6) advises CDC and NCEZID on 
policy and communication matters concerning DFWED programs and 
activities; (7) coordinates, advises, and conducts internal and 
external communications activities for the division, including 
communication research, public affairs, social media, and web; (8) 
leads and manages consumer food safety education for the division, 
including representing cross-cutting CDC consumer food safety education 
efforts with governmental, private, and international organizations; 
(9) provides statistical support across the division by developing 
novel methods or adapting existing methods for assisting in outbreak 
investigations, disease surveillance efforts, research studies, and 
developing statistical acumen of staff; (10) coordinates the division's 
data management and informatics efforts to align with division and 
agency data and surveillance priorities; (11) facilitates the division 
capacity-building program activities under the Epidemiology and 
Laboratory Capacity (ELC) Cooperative Agreement including providing 
guidance and technical assistance to state, local, and territorial 
agencies about implementing foodborne, waterborne, and other enteric 
disease surveillance and response activities; (12) supports the 
development, implementation, and evaluation of model practices and 
quality improvement initiatives associated with division's capacity 
building activities; (13) defines and implements division-wide priority 
prevention efforts; (14) collaborates with Federal agencies and 
industry partners to support related external activities; (15) provides 
oversight for CDC involvement in the World Health Organization (WHO) 
International Food Safety Authorities Network and training in 
foodborne, waterborne, and other enteric disease control and 
prevention; (16) provides subject matter expertise on environmental 
research, and promotes and coordinates related research activities at 
CDC and with collaborative partners; (17) provides leadership in 
preventing and controlling foodborne illness by coordinating related 
activities within CDC and with other local, state, Federal, and 
international organizations; (18) advises and supports the activities 
related to development of long-term NCEZID and CDC strategies, 
policies, and budgets for foodborne disease prevention activities; (19) 
allocates and tracks resources, including interagency, within CDC for 
foodborne disease surveillance, outbreak response, applied research, 
education and training; (20) administers and tracks resources for 
foodborne disease prevention and control activities of national 
organizations representing state and local health departments; (21) 
represents NCEZID and CDC programs and prevention policies in meetings 
with governmental, non-governmental, private, and international 
organizations, and (22) enhances interagency coordination and 
collaboration of public health activities with the Food and Drug 
Administration (FDA) and the U.S. Department of Agriculture, including 
through interagency liaisons.
    Enteric Diseases Epidemiology Branch (CRBB). (1) conducts 
surveillance, investigation, analyses, and research on bacterial 
enteric diseases and provides consultations to state and local health 
departments, other Federal agencies, and national and international 
health organizations on pathogens transmitted by food, water, and 
contact with animals or their environments, and from one person to 
another; (2) conducts surveillance for and analyses of summary data on 
outbreaks of acute enteric illness in the United States; (3) devises 
methods and conducts analyses to measure the burden of and trends in 
bacterial enteric diseases, with a special focus on those transmitted 
by food; (4) devises methods and conducts analyses to attribute 
bacterial enteric illnesses to specific food categories; (5) as part of 
the National Antimicrobial Resistance Monitoring System (NARMS), 
conducts surveillance, investigation, analyses, and research on 
antimicrobial resistance in bacterial enteric organisms, including 
measurements of trends; (6) performs studies to determine risk factors 
for, and host and etiologic agent factors related to, bacterial enteric 
diseases; (7) coordinates and collaborates in national and 
international enteric disease surveillance, training, and studies; (8) 
coordinates the investigation and control of enteric diseases with 
other CDC groups and with other U.S. Federal and local government 
agencies, state health departments, and international health agencies; 
(9) participates with other CDC groups, state health departments, 
regulatory agencies, industry, and other groups in determining and 
assessing the effectiveness of prevention strategies for acute 
bacterial enteric diseases; (10) prepares and disseminates health 
communication materials on the prevention of acute bacterial enteric 
diseases and their long-term health effects; and (11) provides 
information and expert advice to policy makers about bacterial enteric 
diseases and their acute and long-term health effects.
    Enteric Diseases Laboratory Branch (CRBC). (1) uses molecular 
surveillance to identify problems and track trends in foodborne and 
diarrheal diseases; (2) maintains expertise in microbiology, molecular 
biology, immunology, and microbial pathogenesis of organisms that cause 
foodborne and diarrheal diseases; (3) coordinates PulseNet, a network 
of public health laboratories created to build capacity to identify, 
investigate, and control health threats across the nation; (4) informs 
outbreak investigations, other public health investigations, and 
applied research to identify risk factors and improved prevention 
strategies; (5) detects and characterizes bacterial enteric pathogens, 
including Clostridium botulinum, that could be involved in 
unintentional or bioterrorism events (6) conducts surveillance, 
investigation, analyses, and research on antimicrobial resistance, 
including managing the laboratory component of the NARMS at CDC; (7) 
improves methods for and utilization of laboratory-based

[[Page 44321]]

surveillance; (8) uses laboratory and other data to guide control and 
prevention strategies for foodborne and diarrheal illness; and (9) 
partners with reference laboratories throughout the world to build 
capacity for the diagnostic and molecular surveillance of foodborne 
infections both domestically and internationally.
    Outbreak Response and Prevention Branch (CRBD). (1) provides 
epidemic aid, investigation, analysis, and consultation on foodborne 
and zoonotic diseases outbreaks to state and local health departments, 
other Federal agencies, and national and international health 
organizations; (2) coordinates outbreak response activities within the 
Enteric Diseases OutbreakNet, a national network of epidemiologists and 
other public health officials who investigate outbreaks of foodborne, 
zoonotic, waterborne, and other enteric illnesses in the United States; 
(3) coordinates the investigation and control of enteric health 
problems with other CDC groups, and within other U.S. Federal and local 
government agencies, state health departments, and foreign health 
agencies; (4) develops and evaluates prevention strategies for 
foodborne and zoonotic diseases in consultation with regulatory 
agencies, industry, and other health agencies; (5) develops, evaluates, 
and supplies outbreak investigation tools and training materials for 
state and local health departments; (6) supervises EIS field 
investigations; (7) prepares and disseminates health communications 
materials on the control and prevention of foodborne and zoonotic 
disease outbreaks; and (8) provides information and expert advice to 
policy-makers and regulatory authorities on the control and prevention 
of foodborne and zoonotic disease outbreaks.
    Waterborne Disease Prevention Branch (CRBE). (1) identifies, 
tracks, and assesses risk factors, causes, and sources of water, 
sanitation, and hygiene (WASH)-related illness cases and outbreaks; (2) 
prepares for and responds to water-related emergencies and disease 
outbreaks, provides assistance and capacity to state and local health 
departments, other Federal agencies, national ministries of health, and 
international health organizations; (3) develops appropriate sampling, 
detection, tracking, and assessment methods for clinical, water, and 
other environmental specimens; (4) develops and evaluates methods for 
pathogen inactivation or removal; (5) provides diagnostic and clinical 
consultation services for waterborne protozoan parasitic infections; 
(6) develops, monitors, and evaluates existing and new public health 
interventions; (7) develops clear health promotion strategies, 
campaigns, and messages; (8) provides partners with technical and 
capacity building assistance; (9) leads national surveillance systems 
for WASH-related diseases and outbreaks; (10) collects data for public 
health policy development and evaluation; and (11) coordinates with 
Federal agencies and partner organizations on WASH-related disease 
prevention efforts.
    Mycotic Diseases Branch (CRBG). (1) provides epidemic aid, 
surveillance, laboratory support, and consultation on the prevention 
and control of established, emerging, reemerging, and opportunistic 
mycotic (i.e., fungal) diseases; (2) provides reference and diagnostic 
support for agents causing mycotic diseases and for the identification 
of unknown mycotic isolates associated with human disease; (3) 
coordinates and collaborates with state and local health departments, 
other Federal agencies, and national and international health 
organizations in order to detect, respond to, and prevent mycotic 
diseases; (4) evaluates methods for the detection of established, 
emerging, reemerging, and opportunistic mycotic diseases; (5) develops, 
implements, and evaluates prevention and control strategies for these 
diseases; (6) collaborates with other CDC Centers, Institute, and 
Offices (CIOs), NCEZID divisions, state and Federal agencies in 
addressing reemerging mycotic diseases; and (7) provides information 
and expert advice to policy-makers and regulatory authorities on the 
control and prevention of mycotic diseases outbreaks
    Division of Global Migration Health (CRC). The mission of the 
Division of Global Migration Health (DGMH) is to reduce morbidity and 
mortality among immigrants, refugees, travelers, expatriates, and other 
globally mobile populations, and to prevent the introduction, 
transmission, and spread of communicable diseases through regulation, 
science, research, emergency preparedness, and response. In carrying 
out its mission, DGMH: (1) administers a national public health program 
to protect the United States against the introduction of diseases from 
foreign countries and the transmission of communicable disease between 
states; (2) administers an overseas program for the medical examination 
of immigrants, refugees, and as necessary, other migrant populations 
applying for legal entry to the United States, to identify those with 
inadmissible health conditions that would pose a threat to public 
health and impose a burden on public health and hospital facilities; 
(3) conducts public health surveillance, research, and prevention 
programs to detect, prevent, and minimize morbidity and mortality among 
globally mobile populations entering and leaving the U.S.; (4) 
maintains liaison with other Federal agencies, state and local health 
departments, and other partners, and provides information on global 
migration and public health threats related to travel and migration and 
on requirements under CDC's authority and International Health 
Regulations (IHR); (5) serves as a liaison with international health 
organizations and participates in the development of international 
agreements affecting the health of globally mobile populations; (6) 
develops, enforces, and evaluates policies necessary for implementation 
of Federal quarantine authorities protecting the public's health 
through actions taken at ports of entry (POE) or for travelers entering 
or traveling interstate within the United States or of CDC-regulated 
items; (7) conducts studies to provide new information about health 
hazards abroad, measures for their prevention, and the potential threat 
of disease introduction into the United States, and develops 
educational materials for travelers and travel medicine providers; (8) 
provides logistic support to other programs of the CDC in the 
distribution of requested therapeutics available under CDC-maintained 
investigational new drug protocols and movement of biological specimens 
through U.S. POE; (9) advances preparedness and response for public 
health emergencies and threats associated with the introduction of 
diseases from foreign countries and the transmission of communicable 
disease between states; and (10) provides staffing and support for 
emergency responses at program, division, Center, and agency levels.
    Office of the Director (CRC1). (1) manages, directs, and 
coordinates the strategies and activities of the division; (2) provides 
scientific leadership including oversight of scientific integrity and 
quality and health equity; (3) directs development of division policy, 
program planning, and partnerships, and implements regulatory 
responsibilities,; (4) identifies needs and resources for new 
initiatives and assigns responsibilities for their development; (5) 
coordinates liaison with international health organizations, other 
Federal agencies, state and local health departments, and interested 
industries on matters related to travel and migration; (6) provides 
support for the administration of interstate and foreign quarantine 
regulations and compliance with the IHR; (7)

[[Page 44322]]

coordinates division emergency preparedness, readiness, response 
guidance and operations for international and domestic public health 
incidents; (8) reviews and evaluates all administrative services for 
headquarters, border health stations, and overseas offices, and 
provides policy procedures and guidance on such matters; (9) provides 
communication strategy and product development; (10) coordinates 
division strategic workforce and Diversity, Equity, Inclusion, 
Belonging, and Accessibility objectives, and (11) supports science with 
data, advanced analytics, and technology.
    Division of Healthcare Quality Promotion (CRD). The mission of the 
Division of Healthcare Quality Promotion (DHQP) is to protect patients; 
protect healthcare personnel; and promote safety, quality, 
preparedness, resilience, equity, and value in both national and 
international healthcare delivery systems. In carrying out its mission, 
DHQP: (1) measures, validates, interprets, and responds to data 
relevant to healthcare-associated infections (HAI); antimicrobial use 
and resistant infections; sepsis, adverse drug events; blood, organ and 
tissue safety; and immunization safety; environmental hygiene; and 
other related topics and adverse events in healthcare settings; (2) 
leads responses to, investigates and addresses emerging problems and 
infections, antimicrobial resistance, and related adverse events among 
patients and healthcare personnel, and in communities affected by 
antimicrobial resistant or healthcare-associated pathogens; (3) 
develops and maintains the National Healthcare Safety Network (NHSN), a 
national system for monitoring healthcare-associated infections, 
antimicrobial use and resistance, measuring healthcare outcomes and 
processes, and monitoring healthcare personnel vaccination and selected 
health measures in healthcare facilities; (4) assesses local, regional, 
national scope and burden of infections caused by antimicrobial 
resistant-bacteria in the United States and internationally, through 
surveillance and special studies, review of healthcare data sets, and 
laboratory surveillance programs; (5) conducts epidemiologic, and basic 
and applied laboratory research to identify new strategies to detect, 
track, and prevent infections/antimicrobial resistance, and related 
adverse events or medical errors, including those associated with the 
safety of medical or surgical procedures, indwelling medical devices, 
medical product contamination, dialysis, healthcare environments and 
water; (6) collaborates with academic, industry, and government 
partners to design, develop, and evaluate new public health approaches 
to monitoring infections and the efficacy of interventions for 
preventing infections, improving antibiotic use, and reducing 
antimicrobial resistance, and related adverse events or medical errors; 
(7) develops and disseminates evidence-based guidelines and 
recommendations to prevent and control HAI, antimicrobial resistance, 
and related adverse events in healthcare settings; (8) collaborates 
with Federal, state, and local public health and private partners to 
promote nationwide implementation of CDC Guidelines and other evidence-
based interventions to prevent HAI, antimicrobial resistance, and 
related adverse events or medical errors among patients and healthcare 
personnel; (9) evaluates the impact of evidence-based recommendations 
and interventions across the spectrum of healthcare delivery sites; 
(10) serves as the DFO for, provides technical support to, and manages 
the Healthcare Infection Control Practices Advisory Committee (HICPAC); 
(11) serves as the National Reference Laboratory for the identification 
and antimicrobial susceptibility testing of staphylococci, anaerobic 
bacteria, non-tuberculous mycobacteria, and gram-negative bacilli 
causing healthcare-associated and related community infections; (12) 
serves as the technical reference laboratory for detection and 
characterization of other pathogens related to healthcare, and for 
characterizing the contribution of the healthcare environment to HAI 
and antimicrobial resistant infections, and impacts on surrounding 
communities; (13) serves as a global resource for healthcare associated 
infections, antimicrobial resistance, and environmental hygiene; (14) 
coordinates guidance and research related to infection control and 
antimicrobial resistance across the agency and with national and 
international partners; (15) monitors vaccine safety and conducts 
research to evaluate the safety of available and new vaccines; (16) 
trains EIS Officers, Laboratory Leadership Fellows, and other trainees 
in national public health; (17) coordinates agency-wide antimicrobial 
resistance activities and investments; (18) works in a national 
leadership capacity with public and private organizations to enhance 
antimicrobial resistance prevention and control, surveillance and 
response, and applied research; (19) coordinates and provides expertise 
and investigative capacity for blood, organ, and other tissue safety 
issues at CDC; (20) provides expertise and assistance to HHS and other 
Federal agencies and global partners on efforts and activities related 
to safe healthcare; (21) leads international healthcare quality 
improvement and infection control efforts; (22) represents CDC in 
international convenings related to healthcare quality and 
antimicrobial resistance; (23) leads the partnerships between CDC and 
other HHS counterparts on healthcare quality topics and activities; 
(24) builds and supports HAI and antimicrobial resistance prevention 
and control efforts of state and local public health entities and 
laboratories; (25) delivers tailored consultation and training content 
to healthcare facilities and personnel across the spectrum of US 
healthcare; (26) assesses and improves safety of healthcare personnel 
related to HAI and related threats; (27) assesses and improves equity 
in healthcare delivery; (28) improves the effectiveness and safety of 
healthcare practices, protocols, systems, and equipment use related to 
infection prevention and control; (29) coordinates infection prevention 
and control content for non-pharmaceutical interventions across 
community settings; and (30) provides staffing and support for 
emergency responses at program, division, Center, and agency levels.
    Office of the Director (CRD1). (1) manages, directs, and 
coordinates the activities of DHQP; (2) provides strategic direction 
and coordination of communication, policy, and partnership programs and 
activities; (3) provides leadership and guidance on policy impacting 
patient and healthcare safety; (4) leads targeted patient safety 
communication campaigns coordinated with release of CDC surveillance 
data, infection control guidelines, national and international 
healthcare related response activities, research and policy 
publications, and prevention tools; (5) fosters strategic partnerships 
with clinical professional organizations, academic entities, research 
institutes, healthcare systems, consumers and other partners to 
eliminate HAI and related adverse events, prevent sepsis, combat 
antimicrobial resistance, improve health system equity and resilience; 
(6) leads and ensures accuracy of DHQP content for communication/media 
outreach, crisis communications, CDC web content, and content for 
social media platforms; (7) works with Federal agencies, international 
organizations, and other partners on activities related to safe

[[Page 44323]]

healthcare; (8) monitors, supports, and connects state activities to 
track and prevent HAI and antimicrobial resistance; (9) identifies 
consensus goals and implements portfolio management across DHQP 
programs to meet those goals; (10) oversees the quality of DHQP 
research and scientific activities and identifies knowledge gaps; (11) 
provides leadership and strategic planning for program growth and 
development; (12) provides administrative and program services, 
managerial and operations support, and coordination with the 
appropriate CIOs and CDC staff offices on administrative and program 
matters including budget formulation and execution and human resource 
management; (13) oversees the coordination of Federal and state 
programs and new initiatives to prevent HAI, immunization safety, other 
healthcare adverse events, and antimicrobial resistance; (14) 
interprets general program and administrative policy directives for 
implications on management and execution of DHQP programs; (15) serves 
as lead and primary contact and liaison with relevant CDC staff offices 
for procurement requirements; (16) provides management and coordination 
for DHQP-occupied space and facilities including laboratory space and 
facilities; (17) provides oversight and management of the distribution, 
accountability, and maintenance of CDC property and equipment including 
laboratory property and equipment; (18) advises the Director, NCEZID, 
on science, policy and communication matters concerning DHQP activities 
and subject areas; (19) provides program and Federal advisory committee 
administrative support for HICPAC; (20) serves as a division and agency 
resource for systematic evidence review, analysis, and guideline 
production for infection prevention and control; and (21) coordinates 
infection prevention and control (IPC) content for non-pharmaceutical 
interventions across community settings.
    Antimicrobial Resistance Coordination and Strategy Unit (HRD12). 
(1) oversees the coordination of antimicrobial resistance activities at 
CDC to meet national goals; (2) represents CDC in interagency 
activities on Antimicrobial Resistance including the President's 
Advisory Committee for Combatting Antibiotic Resistant Bacteria; (3) 
coordinates with other agencies, state and national governments, 
medical societies, and other public and private organizations to 
enhance domestic and international antimicrobial resistance prevention 
and control, surveillance and response, and applied research; (4) 
represents CDC at the Transatlantic Task Force on Antimicrobial 
Resistance (AR); (5) oversees CDC AR budget to implement AR activities 
as part of the Federal Action Plan to Combat Antibiotic Resistant 
Bacteria; (6) coordinates policies and communications of programs 
across CDC related to antimicrobial resistance; (7) ensures 
coordination with appropriate CIOs and CDC staff offices on AR program 
matters including budget formulation and execution; (8) provides 
updates and reports about CDC AR activities and progress to CDC 
Director, HHS, and the White House; (9) oversees coordination of CDC 
collaborations and new Federal initiatives to detect, respond and 
prevent antimicrobial resistance; and (10) oversees and coordinates 
activities of the Antimicrobial Regional Laboratory Network (ARLN), 
including the AR regional labs across CDC and with states and partners 
and the Global Antimicrobial Laboratory and Response Network with 
countries and international partners.
    Immunization Safety Office (CRDB). Assesses the safety of new and 
currently available vaccines received by children, adolescents and 
adults using a variety of strategies: (1) conducts ongoing surveillance 
for the timely detection of possible adverse events following 
immunization (AEFI) in collaboration with the Food and Drug 
Administration, through implementation and management of the Vaccine 
Adverse Event Reporting System, the national reporting system that acts 
as an early-warning system to detect health conditions that might be 
associated with an immunization; (2) coordinates, further develops, 
maintains and directs activities of the Vaccine Safety Datalink (VSD), 
a collaborative effort with integrated healthcare organizations able to 
perform rapid epidemiologic research on potential causality for AEFI 
using the VSD and other data sources, provide national estimates of 
incidence of AEFI, and determine background rates of health conditions; 
(3) leads the nation in developing biostatistical methods for research 
of AEFI using large linked databases and other data sources, and shares 
methods for use by other agencies and public and private entities; (4) 
conducts clinical research to identify causes of adverse events after 
immunization, specific populations susceptible to specific adverse 
events, and prevention strategies through the DHQP supported Clinical 
Immunization Safety Assessment network, a national network of medical 
research centers, and through other research efforts; (5) applies 
findings from epidemiologic and clinical studies to develop strategies 
for prevention of AEFI; (6) provides global consultation and leadership 
for the development, use, and interpretation of vaccine safety 
surveillance systems, and for the development of shared definitions of 
specific health outcomes through participation in the Brighton 
Collaboration and other international organizations; (7) provides data 
for action to HHS, the Federal Advisory Committee on Immunization 
Practices (ACIP), the FDA's Vaccine and Related Biological Products 
Advisory Committee, Health Resources and Services Administration's 
Advisory Commission on Childhood Vaccines, and international 
collaborators including the WHO Global Advisory Committee on Vaccine 
Safety; and (8) provides timely, accurate communication and education 
to partners and the public on vaccine safety issues.
    Clinical and Environmental Microbiology Branch (CRDC). (1) leads 
national laboratory characterization of HAI-related threats in 
partnership with state and regional laboratories; (2) provides 
comprehensive laboratory support and expertise for investigations of 
recognized and emerging pathogens in healthcare settings, such as 
methicillin-resistant S. aureus, carbapenem-resistant 
Enterobacteriaceae, and Clostridium difficile; (3) provides laboratory 
response to outbreaks and emerging threats associated with infections/
antimicrobial resistance and related adverse events throughout the 
healthcare delivery system; (4) innovates methodologies determining 
environmental contribution to healthcare related outcomes, assesses 
environmental hygiene, and develops methods to assess contamination of 
environmental surfaces and medical devices; (5) investigates novel and 
emerging mechanisms of antimicrobial resistance among targeted 
pathogens found in healthcare settings; (6) conducts research in 
collaboration with partners to develop new, accurate methods of 
detecting antimicrobial resistance in bacteria for early detection of 
emerging resistance; (7) conducts laboratory research to identify new 
strategies to prevent infections/antimicrobial resistance, related 
adverse events, and medical errors, especially those associated with 
invasive medical devices, contaminated products, environmental 
surfaces, air-handling, dialysis, and water; (8) maintains capacity to 
evaluate commercial

[[Page 44324]]

microbial identification and antimicrobial susceptibility testing 
systems and products and facilitates their improvement to provide 
accurate patient test results; (9) investigates the role of biofilms, 
particularly those detected in indwelling medical devices and medical 
water systems, in medicine and public health, and identifies novel 
methods to eliminate colonization and biofilm formation, including on 
medical devices; (10) characterizes and investigates the role of 
microbiomes in the prevention of infections and antimicrobial 
resistance; (11) investigates the role of the water distribution 
systems in healthcare facilities in order to understand and prevent 
transmission of healthcare-associated infections due to water, and the 
impact of healthcare effluents on surrounding environments and 
communities; (12) provides expertise, research opportunities, training, 
and laboratory support for investigations of infections and related 
adverse events to other CDC centers and to partners in areas related to 
quality of clinical microbiology laboratory practices, the 
investigation of emerging pathogens, and environmental microbiology; 
(13) leads ARLN activities related to healthcare pathogens and provides 
assistance to state and regional labs participating in the network; 
(14) maintains and manages the Federal AR Isolate Bank, providing 
access to curated collections of AR pathogens to academic and industry 
partners, including those developing new assays and therapeutics to 
address AR threats; (15) integrates epidemiology of healthcare 
associated pathogens with molecular genetics and whole genome 
sequencing data and bioinformatics to identify, categorize and 
attribute pathogens and related genetic elements relevant to healthcare 
settings; and (16) assesses, supports and implements use of innovative 
technologies and approaches to more accurately and rapidly detect 
healthcare-related pathogens and initiate containment of spread.
    Prevention and Response Branch (CRDD). Across the healthcare 
continuum, including acute, long-term, ambulatory, and chronic care 
settings: (1) develops, promotes, and monitors implementation of 
evidence-based practices, policies, strategies and related educational 
materials to prevent and control HAI and related adverse events 
affecting patients and healthcare personnel, associated with antibiotic 
resistance, device and procedure associated infections, lapses in 
adherence to quality standards and safety, and emerging resistance; (2) 
uses data from the NHSN and other sources to target and improve the 
prevention and control healthcare-associated infections and 
antimicrobial resistance in the United States in specific regions, 
settings and institutions; (3) supports local, state, and national 
efforts to prevent HAI, antimicrobial resistance, and related adverse 
events by providing leadership and technical expertise, including 
assessing effectiveness of CDC-recommended prevention practices; (4) 
provide leadership and epidemiologic support for the investigation, 
monitoring, and control of both recognized and emerging healthcare 
pathogens, including antimicrobial resistant bacteria; (5) leads 
response and control of outbreaks and emerging threats involving HAI 
and related adverse events, contaminated medical products and devices, 
and adverse drug events; (6) communicates the results of response 
activities with Federal and state agencies, healthcare providers, and 
the public, with recommendations to prevent similar adverse events in 
the future; (7) provides leadership, guidance, and technical support to 
and collaborates with other CDC CIOs, other HHS operating divisions, 
and extramural domestic partners, on the epidemiology and prevention 
and control of HAI, antimicrobial resistance and related adverse 
events; (8) manages and directs the national program supporting state 
and local public health agencies to assess and implement activities to 
prevent HAIs and antimicrobial resistance in their jurisdictions; and 
(9) coordinates production of interim infection control guidance for 
emerging infectious threats.
    Surveillance Branch (CRDE). (1) monitors and evaluates the extent, 
distribution, and impact of healthcare-associated infections, 
antimicrobial use and resistance, adverse drug events, healthcare 
preparedness/resilience factors and healthcare worker safety events in 
the United States through the NHSN, providing data to prevent or 
control adverse exposures or outcomes in healthcare; (2) provides 
services, including leadership, consultation, and analytic support to 
investigators in the branch, division, and other organizations applying 
NHSN data to surveillance, research studies, and efforts targeting 
prevention and control of HAI and other healthcare-associated adverse 
events; (3) works with the Centers for Medicare and Medicaid Services 
(CMS) to support CMS payment processes that rely on NHSN data; (4) 
partners with CMS and others to develop new metrics and support 
maintenance of National Quality Forum-approved metrics; (5) 
collaborates with public and private sector partners to further 
standardize, integrate, and streamline systems by which healthcare 
organizations collect, manage, analyze, report, and respond to data on 
HAI, including transmission of multi-drug resistant organisms; (6) 
coordinates, further develops, enables wider use, and maintains NHSN to 
obtain scientifically valid clinical performance indices that promote 
healthcare quality and value at the facility, state, and national 
levels; (7) develops and implements new NHSN modules to track and 
prevent additional healthcare associated harms; (8) provides 
enrollment, security, and user support for over 37,000 NHSN enrolled 
facilities; (9) improves surveillance systems by utilizing new 
technology; and (10) generates and provides NHSN surveillance reports 
and analyses, which include collaborative analytic projects with 
partners.
    Epidemiology Research and Innovations Branch (CRDG). (1) identifies 
and evaluates the efficacy and effectiveness of interventions to 
prevent HAI and related adverse events or medical errors across the 
spectrum of healthcare delivery sites including acute and long-term 
inpatient care, dialysis, and ambulatory settings; (2) identifies gaps 
in HAI-related knowledge and conducts prevention research through the 
Prevention Epicenters cooperative agreements program and Safety and 
Healthcare Epidemiology Prevention Research Development research 
contracts; (3) conducts and supports research and evaluates impact of 
public health practices to prevent HAIs, antimicrobial resistance, 
sepsis and related adverse events; (4) improves methods and enables 
wider use of clinical performance measurements by healthcare facilities 
and public health entities for specific interventions and prevention 
strategies designed to safeguard patients and healthcare workers from 
risk exposures and adverse outcomes through collaborations with 
extramural partners; (5) conducts applied research to identify and 
develop innovative methods, including modeling and economic analyses, 
to detect, characterize, monitor, and predict healthcare threats 
including HAI, sepsis and antimicrobial resistance; and (6) conducts 
special studies to identify and characterize emerging healthcare 
threats working with the Emerging Infections Program and other 
partners.
    Division of High-Consequence Pathogens and Pathology (CRE). The 
Division of High-Consequence

[[Page 44325]]

Pathogens and Pathology (DHCPP) maximizes public health and safety 
nationally and internationally through the diagnosis, prevention, and 
control of disease, disability, and death caused by suspected and known 
viral, bacterial, prion, and related infections. In carrying out its 
mission, DHCPP: (1) conducts surveillance, investigations, and studies 
of viral and bacterial diseases, including bioterrorism agents, as well 
as of transmissible spongiform encephalopathies, or prion diseases, and 
severe diseases of unknown, but suspected infectious, etiology to 
define their etiology and epidemiology, and to develop effective 
methods for diagnosis, treatment, control, and prevention; (2) conducts 
or participates in clinical, field, and laboratory research to develop, 
evaluate, and improve laboratory methods, materials, and therapeutic 
practices used for diagnosis, treatment, control, and prevention of 
viral, bacterial, and prion diseases, including bioterrorism agents; 
(3) conducts research on virus and bacterial transmission to develop 
effective control and prevention strategies and on vaccine 
effectiveness to assess prevention potential; (4) conducts laboratory, 
clinical, and epidemiologic studies of highly hazardous disease agents 
that require biosafety level 3 or biosafety level 4 security for their 
safe handling; (5) conducts ecological studies to develop and evaluate 
disease control and prevention measures; (6) provides epidemic aid, 
epidemiologic consultation, reference and diagnostic services, and 
technical assistance to state and local health departments, other 
Federal agencies, and national and international health organizations; 
(7) provides scientific and technical assistance to other CDC 
components when the work requires unique expertise or specialized 
equipment not available in other components; (8) provides routine and 
specialized laboratory training in the diagnosis, isolation, and 
characterization of viral and bacterial agents to personnel from state 
and local health departments and other national and international 
organizations; (9) provides training opportunities for EIS officers and 
others in CDC sponsored programs, including postgraduate students, 
postdoctoral fellows, and other public health and laboratory 
scientists; (10) provides expert pathological support for various 
infectious diseases to other groups at CDC, state and local health 
departments, and national and international organizations; (11) 
provides staffing and support for emergency responses at program, 
division, Center, and agency levels; and (12) serves as appropriately 
designated national and WHO Collaborating Centers for viral and 
bacterial diseases.
    Division of Infectious Disease Readiness and Innovation (CRG). The 
Division of Infectious Disease Readiness and Innovation (DIDRI) works 
to build and strengthen public health capacity and readiness by 
enhancing the ability of CDC and its public health partners to prepare 
for, prevent, and respond to emerging and reemerging infectious 
diseases, including outbreaks, and other public health emergencies, 
through cross-cutting and innovative programs, technical expertise, and 
public health leadership. In carrying out these activities, DIDRI: (1) 
collaborates with state, tribal, local, and territorial (STLT) health 
departments, and other external groups for infectious disease programs 
and responses to enhance preparedness, and develop innovative responses 
to emerging and reemerging infectious diseases with a goal of 
increasing capacity of STLT health departments; (2) leads national 
wastewater surveillance to understand community-level data on 
infectious diseases and other emerging health issues, and facilitates 
exchange of data with frontline public health practitioners, 
clinicians, decision-makers, key partners, and the public; (3) conducts 
innovative surveillance and other public health practices to detect, 
control, prevent, and respond to emerging infectious diseases; (4) 
supports clinical and public health partners to address health equity 
and rapidly respond to infectious diseases and outbreaks; (5) works 
with infectious disease programs on processes for developing, awarding, 
managing, and evaluating infectious disease grants and cooperative 
agreements; (6) provides subject matter expertise for infectious 
disease and health informatics; (7) conducts analysis of infectious 
diseases using various analytic techniques in coordination with CDC 
infectious disease programs; (8) conducts, supports, and evaluates 
activities aimed at identifying and reducing risk factors for 
infectious diseases overall and among residents of the Arctic and 
Subarctic regions; (9) collaborates with public health partners to 
identify and eliminate health disparities among Alaska Natives, 
American Indians, and indigenous populations; (10) implements the 
Advanced Molecular Disease program by integrating advanced molecular 
technologies into the public health system to strengthen the prevention 
and response to significant public health threats and improve 
identification and characterization of various pathogens; (11) provides 
cross-cutting infectious disease support for evaluation and modeling to 
assess public health impact; (12) establishes integrated and 
sustainable laboratory data and systems that are accessible to all 
public health organizations; and (13) provides staffing and support for 
emergency responses at program, division, Center, and agency levels.
    Office of the Director (CRG1). (1) manages, directs, and 
coordinates the activities of the division, and advises the NCEZID 
Director, NCEZID divisions, and CDC leadership on emerging infectious 
disease science, readiness, response, and innovation; (2) provides 
leadership and guidance on division policy, communication, program 
planning, program management, and operations; (3) provides division-
wide administrative and program services and ensures coordination with 
the appropriate CIO or staff offices on administrative and programmatic 
matters; (4) partners with Federal agencies, STLT health departments, 
international organizations, academic institutions and other external 
groups on readiness and innovative responses to emerging and reemerging 
infectious diseases; (5) ensures coordination of cross-cutting division 
activities with NCEZID divisions, and CDC CIOs; (6) advances health 
equity through scientific and programmatic infectious disease 
activities; and (7) improves the understanding of factors involved in 
infectious disease emergence, prevention, and elimination.
    Arctic Investigations Program (CRGB). (1) conducts, supports, and 
evaluates activities to improve the health of people of the Arctic and 
Subarctic regions, with special emphasis on reducing and preventing 
infectious diseases of high incidence and concern among Alaska Natives 
and American Indians; (2) collaborates with programs across CDC; local, 
state, and tribal partners; the Indian Health Service; and other 
national and international partners to reduce, prevent, and respond to 
infectious disease threats; (3) ensures public health preparedness and 
prevention of infectious diseases by conducting infectious diseases 
surveillance, providing and evaluating prevention services, and 
conducting targeted epidemiologic and laboratory research; (4) works 
with public health partners to identify and eliminate health 
disparities among American Indians, Alaska Natives, and other 
indigenous populations; and (5) provides leadership to improve health 
in the Circumpolar region.

[[Page 44326]]

    Division of Core Laboratory Services and Response (CRH). The 
mission of the Division of Core Laboratory Services and Response 
(DCLSR) is to provide products, services, and specialized expertise to 
CDC programs in support of emergency response activities, laboratory 
research, and laboratory operations. To carry out its mission, DCLSR: 
(1) provides laboratory support to outbreak responses through specimen 
accessioning, pre-clinical processing of diagnostic specimens, surge 
testing capacity, and long-term sample management, including the CDC 
Biorepository; (2) provides laboratory supplies, glassware, mammalian 
tissue cultures, microbiological media, special reagents, and other 
laboratory materials in support of research and service activities to 
laboratories and CDC investigators; (3) promotes animal welfare and 
improves the quality and integrity of animal-based research by engaging 
in independent and collaborative research, providing state-of-the-art 
training to researchers and partners, and offering a broad range of 
fully integrated professional veterinary services; (4) works with CDC 
pathogen-specific programs in the evaluation of existing and in the 
design of innovative and novel diagnostic tests and assays (molecular, 
immunological, and sequence based) and evaluation of new instrument 
platforms and technologies to detect emerging and known pathogens; (5) 
develops and implements applied research programs to expand and enhance 
the use of animal models necessary to support research and diagnostic 
programs and to improve breeding and husbandry procedures; (6) conducts 
applied research in cell biology and in the expansion of tissue culture 
technology as a research and diagnostic tool for infectious disease 
activities; (7) provides services for laboratory investigators in 
protein and DNA synthesis and sequencing, genomic sequencing, 
microarrays, proteomics, and molecular modeling; (8) obtains and 
distributes experimental and orphaned vaccines, drugs, antisera, 
antitoxins, and immune globulins; (9) manages and distributes the 
inventory, maintains the computerized system database, and provides 
general technical service support for the dispensing, lyophilizing, 
capping, and labeling of CDC reference reagents; (10) receives, 
triages, processes, and distributes specimens to CDC laboratories for 
reference diagnostic testing, research studies, and epidemics and 
reports diagnostic test results to submitting organizations; (11) 
manages all CDC exports and ensures compliance with regulations and 
serves as CDC liaison with the Department of Commerce for export-
related issues; (12) produces and distributes specialized reagents and 
diagnostic kits for research and development, surveillance, 
preparedness activities, outbreak and emergency response; (13) provides 
services and expertise in development of quality systems to support 
compliance with FDA regulations on production, distribution, and use of 
laboratory diagnostic reagents; (14) provides liaison activities, 
resources, and expertise for inquiries related to animals and zoonotic 
diseases; (15) provides a centralized activity for tracking requests 
for and distributing select agents to investigators outside of CDC in 
compliance with Federal regulations; and (16) provides staffing and 
support for emergency responses at the program, division, Center, and 
agency levels.
    Office of the Director (CRH1). (1) manages, directs, and 
coordinates the activities of DCLSR; (2) provides leadership and 
guidance on the development of strategic goals, objectives, and 
milestones to advance the vision and mission of DCLSR; (3) distributes 
investigational and licensed drugs and unique biologicals (antitoxins) 
to approved physicians for the treatment of rare, tropical, or 
exceptional diseases; (4) develops administrative policies, processes, 
and operations for the division; (5) ensures that health equity 
principles are applied in all DCLSR activities; (6) works to ensure 
that spending plans and budgets are executed and aligned with the 
strategic priorities of the division; (7) works with NCEZID Office of 
the Director to establish and maintain a diverse, equitable, inclusive, 
and accessible workplace; (8) provides scientific, business, and policy 
oversight and guidance for all programs and activities housed in the 
division; and (9) works closely with other CIOs during outbreak 
investigations and on an ongoing basis, providing support, guidance, 
collaboration, and expertise.
    Division of Vector-Borne Diseases (CRJ). (1) conducts surveillance, 
investigations, and studies of vector-borne viral, rickettsial, and 
bacterial diseases to define disease etiology and to develop effective 
methods and strategies for diagnosis, prevention, and control; (2) 
conducts investigations on the biology, ecology, and control of 
arthropod vectors of viral, rickettsial, and bacterial diseases as a 
basis for development of new and/or modification of existing measures 
for more effective prevention and control; (3) conducts or participates 
in clinical, field, and laboratory studies to develop, evaluate, and 
improve laboratory methods, materials, and therapeutic practices used 
for diagnosis, prevention, and treatment of vector-borne infectious 
diseases; (4) provides epidemic aid and epidemiologic consultation, 
upon request, to state and local health departments, other Federal 
agencies, and national and international health organizations; (5) 
provides reference/diagnostic services for vector-borne viral, 
rickettsial, and bacterial diseases to state and local health 
departments, other Federal agencies, and national and international 
health organizations; (6) conducts research and collaborates on 
development and evaluation of vaccines; (7) provides scientific and 
technical assistance to other CDC components when the work requires 
unique expertise or specialized equipment not available in other 
components; (8) provides intramural and extramural technical expertise 
and assistance in professional training activities; (9) serves as 
designated national and international reference centers for vector-
borne viral, rickettsial, and bacterial diseases; and (10) provides 
staffing and support for emergency responses at program, division, 
Center, and agency levels.
    IV. Under Part C, Section C-B, Organization and Functions, add the 
following functional statements:
    Travel Risk Assessment and Mitigation Branch (CRCB). (1) supports 
and evaluates public health preparedness activities for response to 
communicable diseases at airports, seaports, and land crossings in the 
United States including establishing accords with hospitals to ensure 
adequate isolation and care of persons with certain communicable 
diseases; (2) reviews operations to innovate and use scientific methods 
to inform more effective surveillance and response activities to 
prevent the importation and spread of quarantinable and other 
communicable diseases linked to travel from posing a threat to the U.S. 
population; (3) establishes partnerships and provides technical 
assistance to Federal, state/territorial, industry and international 
partners on domestic and international border health issues; (4) 
enforces public health authorities and collaborates with state and 
local health departments to prevent disease transmission associated 
with travel and offers local officials consultation on isolation, 
quarantine, and other public health interventions in collaboration with 
the Port of Entry Operations Branch; (5) contributes border health 
expertise to the transportation sector in the United States, abroad, 
and to

[[Page 44327]]

multilateral bodies, including sharing recommendations on public health 
risk assessment and management practices, and conducts communications, 
media, and training for the Travel Risk Assessment and Mitigation and 
the Port of Entry Operations team members; (6) develops content for 
websites, videos, and maps to support airport partners and the public 
at POE regarding public health threats and Federal regulations 
delegated to CDC, including providing guidance to partners that 
implement CDC's delegated regulatory authorities at U.S. borders; (7) 
provides epidemiological support for activities related to border 
health and globally mobile populations including implementation of 
analytical projects to build scientific evidence for travel-related 
mitigation measures and dissemination of results for public health 
action; (8) provides technical consultation and develops public health 
training to border health staff and other agencies carrying out Federal 
inspections services at POE to enforce HHS/CDC regulations on 
quarantine; (9) serves as an identified point of contact with Federal 
security agencies when health, travel, and security intersect; and; 
(10) provides medical and veterinary-support to Port of Entry 
Operations Branch team members to respond to illnesses or HHS/CDC-
regulated animals and other importations at POE.
    Immigrant and Refugee Health Branch (CRCC). (1) recommends 
appropriate, effective intervention and prevention strategies to 
decrease morbidity and mortality among globally mobile populations and 
to prevent entry of disease into the United States; (2) implements 
enhanced public health interventions for refugees such as vaccination 
and presumptive treatment programs for intestinal parasites and 
malaria; (3) responds to refugee resettlement health emergencies 
overseas and domestically; (4) oversees, evaluates, and monitors the 
required overseas and domestic medical examinations of immigrants and 
refugees (and others for whom a medical exam is required), and 
prepares, publishes, updates, and distributes Technical Instructions 
for examining physicians; (5) works cooperatively with state health 
departments to form multi-state networks for health surveillance of 
refugees and to develop health guidance for health professionals who 
care for newly arrived refugees; (6) establishes, maintains, and 
evaluates notification procedures regarding immigrants and refugees, 
providing coordination and liaison with local and state health 
departments on the follow-up of those with serious diseases of public 
health significance, in particular notifiable diseases such as 
tuberculosis; (7) conducts continuing review, technical guidance, and 
evaluation of required immigration medical screening procedures to 
ensure the most effective application of current medical practices; (8) 
develops and administers training curricula for examining physicians to 
support rigorous adherence to the CDC Technical Instructions; (9) works 
cooperatively and in concert with other Federal and international 
agencies, voluntary agencies, and foreign governments, both in the 
United States and abroad, in administering required medical screening 
programs for immigrants, refugees, parolees, and non-immigrant visa 
applicants; (10) performs epidemiologic investigations and scientific 
research projects related to health issues for immigrant, refugee, and 
migrant populations; (11) establishes and maintains procedures to 
process requests for waivers for applicants with inadmissible medical 
conditions; (12) works with foreign governments and partners to 
establish or strengthen public health conditions for U.S.-bound 
populations, and other globally mobile populations for the prevention, 
detection, and response to infectious diseases; (13) provides support 
to international government and public health partners to strengthen 
global public health capacity to help prevent the spread of infectious 
diseases; (14) determines and strategically tracks factors that affect 
the health of U.S.-bound or recently arrived refugees, immigrants, and 
migrants through research, evaluation, and high-quality data sources 
and systems; and (15) educates Federal, state, and private agencies 
about health aspects of international child adoption procedures.
    Travelers' Health Branch (CRCD). (1) improves the health of all 
global travelers, including underserved populations, and prevents the 
importation of communicable disease to the United States, the 
Travelers' Health Branch (THB) produces travelers' health 
recommendations for international travelers, healthcare providers, 
employers, and policymakers, (2) produces Travel Health Notices to 
inform travelers and other audiences about global health risks during 
outbreaks, special events or gatherings, and natural disasters, and 
provide advice on protective actions travelers can take to prevent 
infection and other adverse health effects; (3) conduct mapping and 
spatial representation of outbreak areas and areas where diseases are 
endemic; (4) produces the print and online premiere medical textbook on 
travel health medicine used by clinicians and other partners; (5) 
produces and maintains CDC Travelers' Health website, an online 
compendium of travel medicine information and recommendations; (6) 
supports surveillance systems for travel-related illness trends and 
pathogens through collaborations with national and international travel 
clinic networks and the development and evaluation of traveler and 
travel conveyance surveillance sampling and testing strategies for 
pathogen detection and characterization, (7) translates travel medicine 
science into actionable health information recommendations, including 
online educational products, and mobile tools; (8) manages a registry 
of national providers and yellow fever stamp owners, provides guidance 
regarding yellow fever vaccine requirements and recommendations for 
international travelers, and conducts ongoing surveillance for serious 
adverse events following yellow fever vaccination; (9) participates in 
ACIP workgroups regarding vaccines used for travelers and works with 
vaccine producers to ensure availability of travel vaccines; (10) 
collaborates with private partners to analyze global data on disease 
incidence and risk factors among travelers; (11) partners with 
international organizations such as the WHO to establish consensus on 
travel medicine evidence base, disease-specific data repositories, and 
definitions of diseases of relevance to travelers' health; (12) 
participates in emergency responses to provide support for traveler 
issues including surveillance, traveler health prevention and treatment 
recommendations; and (13) performs rapid assessments of available 
epidemiological information to develop public health risk assessment 
and guidance for travelers.
    Port Health Protection Branch (CRCE). As CDC's representative at 
U.S. POE for mitigating biosecurity and emerging infections, (1) 
protects the public's health at U.S. borders and POE by working with 
state and local health departments, ministries of health, the WHO, and 
intergovernmental organizations in collaboration with the Travel Risk 
Assessment and Mitigation Branch; (2) responds to travel-related 
communicable disease threats and develops and implements strategies to 
prevent introduction and spread of diseases of public health concern 
arriving in persons, animals, cargo, and conveyances at U.S. POE; (3) 
documents those activities to provide surveillance

[[Page 44328]]

of public health events occurring at sea, air, and land POE to the 
United States and its possessions; (4) provides public health training 
to field staff and other on-site agencies carrying out Federal 
inspection services at POE to enforce CDC regulations on quarantine, 
apply public health best practices, augment CDC's geographic reach at 
POE, and ensure appropriate occupational safety and health protection 
for their staff; (5) stores and rapidly distributes emergency and 
lifesaving medications not otherwise available for patients in the 
United States and its possessions from designated POE locations; (6) 
provides logistics support to other CDC programs and other partners and 
expedites the movement of persons, clinical specimens, and other 
materials through Federal security and the rest of the Federal 
inspection apparatus; and (7) provides in-person or telephone 
consultative response to public health threats at U.S. POE 24 hours a 
day and seven days a week with support of Quarantine Medical Officer(s) 
and Quarantine Veterinary Officer(s) from the Travel Risk Assessment 
and Mitigation Branch for reports of ill travelers, or problems with 
animals, biological materials, and other CDC regulated importations.
    Southern Border Health and Migration Branch (CRCG). (1) provides 
scientific and technical support to the division and agency's 
operational and public health regulatory and emergency response 
responsibilities concerning infectious diseases among the U.S.-Mexico 
and other Latino binational populations and other globally mobile 
populations traversing the U.S. southern border, the busiest land 
border in the world; (2) focuses on the prevention and control of 
infectious diseases and expanding the health evidence base among the 
dynamic and globally mobile populations that reside in and travel 
through the southern U.S. land border region through activities 
including surveillance, illness response, epidemiologic investigations 
and analyses, and leveraging strategic partnerships and scientific 
collaborations (e.g., other Federal agencies, state and local health 
authorities, international and regional organizations, non-governmental 
organizations, and health authorities from Mexico and other key migrant 
stream countries); (3) supports the division's regulatory activities at 
southern U.S. land points of entry including illness response, animal, 
biologic and etiologic importations that have infectious disease 
implications for human health; (4) expands evidence base and 
intervention support for infectious diseases and health disparities 
among the populations that reside, work, and travel through the 
southern U.S. land border region and other Latino binational 
populations in the United States, including Spanish speaking migrants 
and farmworkers, through targeted education, linguistically appropriate 
health communications, outreach activities, and partnerships; (5) 
supports transnational continuity of care and travel restriction 
decisions for persons with active tuberculosis moving in or out of the 
United States; (6) helps facilitate CDC projects with Mexico (Mexico 
Country Office) and the Central American Region (Panama Office) to 
address priority health issues of mutual interest that will advance 
scientific knowledge, protect binational, regional and migratory 
populations, and facilitate coordinated disease response and health 
security between the public health officials in the United States, 
Mexico, and Central America; and (7) supports binational working 
groups, collaborations, and data systems that support surveillance, 
information sharing, expand evidence base on health disparities and 
control of binational/border communicable diseases of importance, and 
support partnerships with key organizations and governmental agencies 
to enhance service provision to mobile border/binational populations.
    Healthcare Systems Strengthening, Resilience, and Training Branch 
(CRDH). (1) leads, in collaboration with the other appropriate division 
components, development and delivery of training related to the 
prevention of HAIs, antimicrobial resistance, adverse events, and 
medical errors, and improving environmental hygiene, use of personal 
protective equipment, disinfection, sterilization, and other related 
topics with a focus on remote, rural, and underserved areas; (2) builds 
and supports partnerships with organizations that increase reach and 
impact for DHQP training content; (3) identifies and addresses gaps in 
information needed to successfully implement and optimize training and 
IPC in healthcare settings; (4) supports state, local, and Federal 
efforts to establish and improve infection prevention and control 
through training and implementation programs, and policies that support 
IPC resilience; (5) assists partners in improving infection prevention 
and control, HAI surveillance, and environmental hygiene capacities 
through tailored long-term consultative support; (6) provides technical 
assistance for development of organization-specific infection control 
policies and action plans to prevent HAIs and reduce antimicrobial 
resistance; (7) leads healthcare preparedness and resilience planning 
and implementation to enable healthcare facilities to respond to 
infectious disease threats at local, regional and national levels, 
including monitoring and reporting related to acute surges in staffing 
and resource needs, impacts on healthcare personnel, bed and equipment 
availability, and coordination within local jurisdictions; (8) 
coordinates DHQP activities and collaborates with other CIOs and 
Federal agencies to prepare healthcare to respond to emerging threats; 
(9) represents and coordinates DHQP activities for agency-wide 
responses and collaborates with CDC Emergency Operations Center for 
emergency response to emerging infections involving healthcare (e.g., 
Ebola); and (10) provides expert consultation, guidance, and technical 
support to and collaborates with other CDC CIOs, other HHS operating 
divisions.
    International Infection Control Branch (CRDJ). (1) leads, in 
collaboration with the appropriate CDC CIO and other components, global 
health activities related to the prevention of HAIs, antimicrobial 
resistance, and related adverse events or medical errors; (2) 
coordinates international efforts to establish and improve infection 
prevention and control policies, programs, and collaborations; (3) 
assists countries to improve infection prevention and control capacity 
toward prevention and control of endemic and outbreak-related HAIs 
outbreaks; (4) produces tailored implementation and training content to 
support countries and international partners working to improve 
healthcare safety and quality; (5) in collaboration with ministries of 
health, CDC country offices, and implementing partners, develops 
country-specific national policies and action plans to improve 
healthcare safety and reduce the global burden of antimicrobial 
resistance associated with healthcare delivery; (6) provides technical 
assistance to international partners in building diagnostic laboratory 
capacities and surveillance systems; and (7) leads development of 
global networks to detect and contain infectious disease threats 
related to healthcare.
    Medical Product Safety Branch (CRDK). (1) leads CDC's activities on 
blood, organ, and other tissue safety; (2) represents CDC on the 
Advisory Committee on Blood Safety and Availability and the Advisory

[[Page 44329]]

Committee on Organ Transplantation; (3) works with other Federal 
agencies, state governments, and other public and private organizations 
to enhance blood, organ, and other tissue safety through coordination 
of investigation, prevention, response, surveillance, applied research, 
health communication, and public policy; (4) leads CDC's national 
adverse drug events surveillance activities and seeks to translate 
population-based ADE surveillance data into evidence-based policies and 
targeted, innovative and collaborative interventions; and (5) develops, 
promotes, and monitors implementation of and adherence to evidence-
based practices, policies, strategies, and related educational 
materials to increase adherence to optimal antimicrobial use and 
stewardship across all healthcare settings.
    Epidemiology Laboratory Capacity (ELC) and Informatics Branch 
(CRGC). (1) builds the capacity of state, local, and territorial public 
health agencies to prevent and respond to infectious diseases through 
the ELC cooperative agreement; (2) provides scientific and programmatic 
guidance, as well as management, administrative, and technical support 
for broad infectious disease cooperative agreements such as the ELC 
program; (3) serves as a liaison/point of contact to assist recipients 
in identifying appropriate technical assistance; (4) provides program 
expertise, innovation, and linkages for infectious disease and health 
informatics; (5) increases adoption of electronic exchange of public 
health data between CDC and frontline public health agencies; and (6) 
analyzes the effectiveness and impact of infectious disease activities 
in collaboration with other CDC programs with various analytic 
techniques.
    Rapid Response Research and Surveillance Branch (CRGD). (1) 
responds to emerging infectious disease outbreaks and emergencies 
through innovation and by collaborating and partnering with STLT public 
health agencies and providing scientific technical assistance; (2) 
implements wastewater surveillance to provide an early warning for 
emerging infections or public health concerns by coordinating and 
building wastewater surveillance capacity, and providing real-time, 
community-level data to clinicians, decision-makers, key partners, and 
the public; (3) leads and supports infectious disease fellowship and 
training programs; (4) supports health departments and other clinical 
and public health partners on issues related to improving health equity 
and infectious disease rapid response activities and resources; (5) 
conducts surveillance and other novel and innovative public health 
practice activities to detect, control, and prevent emerging infectious 
diseases; and (6) creates study activities and related publications 
that support public health science and response activities and 
interventions.
    Office of Advanced Molecular Detection (CRGE). (1) integrates 
advanced molecular technologies into the public health system, both 
domestically and globally, to enhance the prevention and response to 
significant public health threats and improve the identification and 
characterization of various pathogens; (2) develops innovative tools 
for the detection, characterization, prediction, modeling, and early 
recognition of emerging infectious diseases; (3) establishes enhanced, 
sustainable, and integrated laboratory data and systems that are 
accessible for all public health organizations; (4) builds workforce 
capacity in genomic sequencing, bioinformatics, and molecular 
epidemiology within public health organizations and in partnership with 
the private sector and academia, both domestically and globally; and 
(5) leads ongoing quality initiatives for genomic surveillance 
throughout CDC, including the infectious disease review board and 
quality validation framework.
    Advanced Diagnostics and Biotechnologies Branch (CRHB). (1) 
provides state-of-the-art next-generation genomic sequencing and 
metagenomics analysis of infectious and biothreat agents; (2) provides 
optical mapping to produce high resolution whole- genome maps for 
strain typing, molecular epidemiology, comparative genomics, and 
quality control for whole genome sequence assembly; (3) provides 
computational analysis of genomics sequencing data, bioinformatics, and 
biological computing; (4) provides qualitative and quantitative 
proteomic analyses (identification of expressed proteins by mass 
spectrometry); analysis of functionally-relevant post-translational 
modifications of proteins; (5) provides mass spectrometry-based 
positive identification of bacteria and fungi; (6) provides synthetic 
oligonucleotide chemistry in support of development of rapid diagnostic 
tests and characterization of pathogens and their hosts; (7) provides 
synthetic peptide chemistry in support of studies of immune response 
and antigen-antibody interactions; (8) provides biotechnology seminars 
and methods evaluation; (9) works with CDC pathogen-specific programs 
in the evaluation of new instrument platforms and technologies to 
detect emerging and known pathogens and in the evaluation of existing 
and in the design of innovative and novel diagnostic tests and assays 
(sequence based); (10) provides laboratory equipment design and repair 
services to all CDC; and (11) assesses and supports advanced analytical 
methodologies for the CDC scientific community.
    Preparedness, Response, and Outbreak Services Branch (CRHD). (1) 
provides centralized specimen management services for diagnostic, 
reference, and outbreak investigations; maintains a bank of biological 
specimens of epidemiological significance to CDC's research and 
diagnostic activities; manages and tracks systems of specimen 
collections; (2) receives, triages, processes, stores, and distributes 
specimens to CDC laboratories for reference diagnostic testing, 
research studies, and reports diagnostic and surveillance test results 
to submitting organizations; (3) provides extracted nucleic acids under 
a Clinical Laboratory Improvement Amendments approved workflow that can 
be used for sequencing and molecular diagnostics; (4) maintains and 
manages the biological laboratory component of the Laboratory Response 
Network (LRN); (5) provides LRN strategic guidance, leadership, and 
operations support; (6) provides technical input for assay development 
for federally managed environmental monitoring systems and guidelines 
developed through U.S. government collaborations for the validation and 
use of environmental detection devices; (7) develops LRN protocols for 
specimen handling and testing for bioterrorism agents; (8) produces and 
manages inventory of high-quality reagents available to LRN 
laboratories and expedites shipping of products to support emergency 
response needs; (9) collaborates with CDC and external partners to 
assist in administering proficiency testing programs for critical 
agents for LRN member laboratories; (10) evaluates and validates 
advanced technology for the identification and characterization of 
agents of bioterrorism and other emerging infectious diseases; (11) 
works with CDC pathogen-specific programs in the evaluation of existing 
and in the design of innovative and novel diagnostic tests and assays 
(molecular and immunological); (12) provides laboratory triage 
capability at CDC for unknown biological and chemical agents; (13) 
produces hybridomas, monoclonal and polycolonal antibodies, and in 
vitro diagnostic products for

[[Page 44330]]

diagnostic research purposes, proficiency testing, pandemic 
preparedness, outbreak response and surveillance activities; (14) 
collaborates with subject matter experts in regulatory compliant 
development, production, packaging, storing and distribution of 
Biosafety Level 2 (BSL2)/Biosafety Level 3 (BSL3) reagents, select 
agents, novel immuno-chemical reagents and reference diagnostic 
reagents; (15) provides dispensing, lyophilizing, label production, and 
device assembly services; (16) improves the process of bench-top 
development and in-house pilot scale production providing immediate 
availability for distribution, preventing backorders and streamlining 
commercialization; (17) packages and ships infectious substances and 
other materials, ensuring compliance with regulations for shipping 
clinical specimens, infectious substances, and other materials; (18) 
operates the CDC Biorepository as a centralized resource to preserve 
CDC's valuable samples and provide ongoing support to CDC programs; 
(19) manages sample collections, along with associated information and 
data obtained from CDC's public health surveillance, research, and 
outbreak responses; (20) serves as the administrator issuing CDC's 
required standardized identifiers: the CDC Sample Identifier and CDC 
Unique Identified; and (21) provides consultation in all of the above 
technical services.
    Laboratory Products and Services Branch (CRHE). (1) maintains 
laboratory water treatment systems to ensure quality of CDC reagent 
grade laboratory water; (2) produces, develops, evaluates, and 
distributes custom microbiological and cell culture media, buffers, and 
chemical reagent, mammalian, and insect cell cultures; (3) maintains 
CDC's Biological Reference Reagent Inventory, mammalian cell line 
repository and a serviceable inventory at the DCLSR Continuity of 
Operations storage facility; (4) packages and ships infectious 
substances and other materials, ensuring compliance with regulations 
for shipping clinical specimens, infectious substances, and other 
materials; (5) manages all CDC exports and ensures compliance with 
regulations and serves as CDC liaison with Department of Commerce for 
export-related issues; (6) oversees laboratory waste management; (7) 
coordinates laboratory glassware and stockroom operations, consumables; 
and (8) provides consultation in all of the above technical services.
    Division of Parasitic Diseases and Malaria (CRK). The Division of 
Parasitic Diseases and Malaria (DPDM) prevents and controls parasitic 
diseases in the United States and throughout the world by providing 
diagnostic, consultative, epidemiologic services, and training. In 
carrying out its mission, DPDM: (1) conducts surveillance, 
investigations, and studies of parasitic diseases to define disease 
etiology, mode of transmission, and populations at risk, and to develop 
effective methods for diagnosis, prevention, control, and elimination; 
(2) conducts or participates in clinical, field, and laboratory 
research to develop, evaluate, and improve laboratory methodologies, 
materials and therapeutic practices used for rapid and accurate 
diagnosis and treatment of parasitic diseases; (3) provides epidemic 
aid, epidemiologic consultation, and reference diagnostic services to 
state and local health departments, other Federal agencies, and 
national and international health organizations; (4) conducts a program 
of laboratory and field research in the biology, ecology, and host-
parasitic relationships to develop better methods for diagnosis, 
prevention, and control of parasitic diseases; (5) coordinates with the 
U.S. Agency for International Development to address neglected tropical 
diseases and to achieve the goals of the President's Malaria 
Initiative; (6) provides scientific and technical assistance to other 
components within CDC when the work requires unique expertise or 
specialized equipment not available in other CDC components; (7) serves 
as WHO Collaborating Centers for Cysticercosis, Research Training and 
Eradication of Dracunculiasis, Control and Elimination of Lymphatic 
Filariasis, Evaluating and Testing New Insecticides, Insecticide 
Resistance, Insect Vectors; Malaria Control in Africa, Human African 
Trypanosomiasis, Production and Distribution of Malaria Sporozoite 
enzyme-linked immunosorbent assay; (8) maintains field-based research 
and program activities in numerous developing countries; (9) provides 
communications support for responsive, evidence-based information 
targeted to the public, local and state health officials, international 
partners, and private organizations to inform health decisions, to 
prevent, and control parasitic diseases in the United States and 
abroad; and (10) provides staffing and support for emergency responses 
at program, division, Center, and agency levels.
    Office of the Director (CRK1). (1) works with NCEZID Office of the 
Director to ensure spending plans and budget are in line with the 
overall infectious disease strategies and priorities; (2) ensures that 
the NCEZID strategy is executed by the division and aligned with 
overall CDC goals; (3) co-develops execution strategies for the 
division with the branch chiefs; (4) provides program and science 
quality oversight; (5) builds leadership at the division and branch 
levels; (6) evaluates the strategies, focus, and prioritization of the 
division research, program, and budget activities; (7) identifies and 
coordinates synergies between the division and relevant partners; (8) 
ensures that policy development is consistent and appropriate; (9) 
facilitates research and program activities by providing leadership 
support; (10) proposes resource priorities throughout the budget cycle; 
(11) ensures scientific quality, ethics, and regulatory compliance; 
(12) fosters an integrated approach to research, program, and policy 
activities; and (13) liaises with HHS and partners.
    Malaria Branch (CRKB). (1) conducts malaria surveillance, 
prevention, and control in U.S. residents and visitors by monitoring 
the frequency and distribution of malaria cases that occur in U.S. 
residents and visitors and the efficacy and safety of antimalarial 
drugs for chemoprophylaxis and chemotherapy; (2) provides clinical 
advice and epidemiologic assistance on the treatment, control, and 
prevention of malaria in the United States and in malaria-endemic 
countries; (3) provides information to the U.S. public and to 
appropriate agencies and groups on appropriate measures to prevent and 
control malaria; (4) provides consultation, technical assistance, and 
training to malaria-endemic countries and to international and U.S. 
agencies and organizations on issues of malaria prevention and control; 
(5) conducts epidemiologic, and field-based research projects, 
including laboratory and field studies on parasitic diseases to define, 
transmission dynamics, populations at risk, and determinants of 
morbidity and mortality; (6) conducts field studies of malaria 
prevention and control tools and strategies; and (7) conducts 
assessments of malaria monitoring and evaluation methods and program 
use of these methods.
    Parasitic Diseases Branch (CRKC). (1) investigates outbreaks and 
unusual occurrences of parasitic diseases in concert with states, 
ministries of health, WHO, and other agencies and organizations; (2) 
conducts surveillance of parasitic diseases in the United States, 
including foodborne parasitic disease outbreaks; (3) provides 
consultation on the prevention, treatment, and management of parasitic 
diseases to clinicians, laboratorians,

[[Page 44331]]

departments of health, and other agencies; and provides otherwise 
unavailable anti-parasitic drugs to healthcare providers and ensures 
compliance with FDA's regulations; (4) supports the agency's overall 
emergency response mandate; (5) conducts field and laboratory 
investigations and research on the etiology, epidemiology, chemotherapy 
and other aspects of parasitic diseases to develop new tools for 
identifying and controlling parasitic diseases; (6) carries out and 
evaluates operational research to evaluate current strategies and 
develops new strategies to support programmatic activities for the 
control and elimination of parasitic diseases, and provides technical 
assistance to ministries of health, WHO, and other agencies and 
organizations for these programs; (7) provides training to EIS 
officers, Preventive Medicine Residents, public health prevention 
specialists, and other fellows and students; and (8) prepares and 
disseminates health communication materials on the prevention and 
treatment of parasitic diseases.
    Entomology Branch (CRKD). (1) conducts global surveillance, field 
investigations, and laboratory studies on the vectors of parasitic 
diseases of humans, with a focus on malaria, Chagas' disease, lymphatic 
filariasis, onchocerciasis, and leishmaniasis, with a particular 
emphasis on the anopheline vectors of malaria; (2) serves as WHO 
Collaborating Centers for pesticides resistance, anopheline vector 
identification, antimalarial drug evaluation, and vector control; (3) 
develops methods supporting the global use of pesticides for control of 
vector-borne diseases, the management of insecticide resistance, and 
the monitoring of anti-parasitic drugs; (4) serves as an international 
reference reagent and anopheline vector repository, providing 
materials, training, and information related to malaria vectors; and 
(5) provides entomological consultation, epidemic aid, and training to 
local, state, Federal and foreign agencies and international health 
organizations on surveillance and control of malaria and parasitic 
vector-borne diseases.
    Laboratory Science and Diagnostics Branch (CRKE). (1) provides 
reference and laboratory diagnostic services to physicians and 
laboratories; (2) transfers technologies and expertise in laboratory 
diagnosis of parasitic infections to public health laboratories; (3) 
supports the agency's overall emergency response mandate; (4) conducts 
field and laboratory investigations and research on the biology, 
ecology, pathogenesis, immunology, genetics, host-parasite 
relationships, and other aspects of parasitic diseases to develop new 
tools for identifying and controlling parasitic diseases; (5) develops 
and tests new laboratory methods and tools for improved diagnosis, 
control, and prevention of parasitic diseases, and conducts laboratory 
training courses for public health laboratories; (6) conducts 
laboratory, and field-based research projects, including laboratory and 
field studies on parasitic diseases to define biology, ecology, 
parasite species differences, host-parasite relationships, diagnostics, 
host immune responses; (7) conducts laboratory studies of malaria 
parasites utilizing animal models and in vitro systems for parasitic 
relationships, chemotherapy, and vaccine evaluation studies; efficacy 
and safety of antimalarial drugs for chemoprophylaxis and chemotherapy; 
and training to malaria-endemic countries; conducts assessments of 
malaria monitoring and evaluation methods; and (8) provides training to 
Emerging Infectious Disease fellows, American Society of Microbiology/
Postdoctoral Fellows, and other fellows and students.
    V. Under Part C, Section C-B, Organization and Functions, the 
following organizational unit is deleted in its entirety:

 Food Safety Office (CVLB13)
 Quarantine and Border Health Services Branch (CVLCB)
 Immigrant, Refugee, and Migrant Health Branch (CVLCC)
 Geographic Medicine and Health Promotion Branch (CVLCD)
 International Infection Control Activity (CVLD14)
 One Health Office (CVLE13)
 Scientific Programs and Development Branch (CVLGC)
 Emergency Preparedness and Response Branch (CVLGD)
 Laboratory Preparedness and Response Branch (CVLGG)
 Biotechnology Core Facility Branch (CVLHD)
 Reagent and Diagnostic Services Branch (CVLHG)

Delegations of Authority

    All delegations and redelegations of authority made to officials 
and employees of affected organizational components will continue in 
them or their successors pending further redelegation, provided they 
are consistent with this reorganization.

(Authority: 44 U.S.C. 3101)

Robin D. Bailey, Jr.,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-14704 Filed 7-11-23; 8:45 am]
BILLING CODE 4163-18-P